Sanofi-Aventis SA (SASY.PA) is close to clinching a deal worth around $20 billion to buy Genzyme Corp (GENZ.O), nearly nine months after the French drugmaker first put the idea to the U.S. biotech group. The boards of both companies are scheduled to meet on Sunday to decide on Sanofi's proposed acquisition, according to sources with knowledge of the situation. The deal is expected to be priced at $74 a share in cash, or more than $19 billion, plus a tradable contingent value right, or CVR, with an intrinsic value of $5 to $6 a share, the sources said.
Source
